Litcius/Paper detail

Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes

Pasquale Mone, Angela Lombardi, Urna Kansakar, Fahimeh Varzideh, Stanislovas S. Jankauskas, Antonella Pansini, Stefania Marzocco, Stefano De Gennaro, Michele Famiglietti, Gaetano Macina, Salvatore Frullone, Gaetano Santulli

2022Journal of Pharmacology and Experimental Therapeutics101 citationsDOIOpen Access PDF

Topics & Concepts

EmpagliflozinMedicineHeart failure with preserved ejection fractionMetforminInternal medicineEndothelial dysfunctionDiabetes mellitusEjection fractionCardiologyType 2 diabetesHeart failuremicroRNAInsulinEndocrinologyBiologyBiochemistryGeneDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerMicroRNA in disease regulation
Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes | Litcius